These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17329198)

  • 21. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
    Hayette S; Chabane K; Michallet M; Michallat E; Cony-Makhoul P; Salesse S; Maguer-Satta V; Magaud JP; Nicolini FE
    Leuk Res; 2011 Jan; 35(1):38-43. PubMed ID: 20673586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
    Bauer S; Romvari E
    Clin J Oncol Nurs; 2009 Oct; 13(5):523-34. PubMed ID: 19793709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
    Rodrigues MS; Sattler M
    J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
    [No Abstract]   [Full Text] [Related]  

  • 25. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
    Klamova H; Faber E; Zackova D; Markova M; Voglova J; Cmunt E; Novakova L; Machova-Polakova K; Moravcova J; Dvorakova D; Michalova K; Brezinova J; Oltova A; Jarosova M; Cetkovsky P; Indrak K; Mayer J
    Neoplasma; 2010; 57(4):355-9. PubMed ID: 20429627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
    Bagadi S; Saikia T; Pany A; Das B
    Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [STAT5, a new therapeutic target against the relapse of chronic myelogenous leukemia?].
    Casetti L; Martin-Lannerée S; Najjar I; Dusanter-Fourt I
    Med Sci (Paris); 2013; 29(8-9):693-5. PubMed ID: 24005621
    [No Abstract]   [Full Text] [Related]  

  • 28. New directions in the treatment of imatinib failure and/or resistance.
    Giles FJ
    Semin Hematol; 2009 Apr; 46(2 Suppl 3):S27-33. PubMed ID: 19621547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
    Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract]   [Full Text] [Related]  

  • 33. Chronic myeloid leukemia: advances in diagnosis and management.
    Noronha S; Sawyer S
    JAAPA; 2013 Feb; 26(2):26-9. PubMed ID: 23409382
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
    J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract]   [Full Text] [Related]  

  • 35. The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Leuk Lymphoma; 2007 Apr; 48(4):802-4. PubMed ID: 17454640
    [No Abstract]   [Full Text] [Related]  

  • 36. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
    Okabe S; Tauchi T; Ohyashiki K
    Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Doggrell SA
    Expert Opin Investig Drugs; 2005 Jan; 14(1):89-91. PubMed ID: 15709925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
    Mauro MJ
    Curr Treat Options Oncol; 2007 Aug; 8(4):287-95. PubMed ID: 18157514
    [No Abstract]   [Full Text] [Related]  

  • 39. Chronic myelogenous leukemia for primary care physicians.
    Torgerson SR; Haddad RY; Atallah E
    Dis Mon; 2012 Apr; 58(4):168-76. PubMed ID: 22449366
    [No Abstract]   [Full Text] [Related]  

  • 40. Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
    Inami M; Inokuchi K; Nakayama K; Tamura H; Shimada T; Dan K
    Int J Hematol; 2003 Aug; 78(2):173-5. PubMed ID: 12953816
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.